Jay H. Shubrook, DO, FAAFP, FACOFP - Unlocking the Potential of Incretin-Based Therapies in T2D: Comprehensive Primary Care Strategies for Cardiometabolic Health

About this episode

The episode discusses the potential of incretin-based therapies in managing Type 2 diabetes and strategies for improving cardiometabolic health in primary care.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MVY865. CME/AAPA credit will be available until May 15, 2027. Unlocking the Potential of Incretin-Based Therapies in T2D: Comprehensive Primary Care Strategies for Cardiometabolic Health In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.

People in this episode

Guest: Jay H. Shubrook, DO, FAAFP, FACOFP

Topics covered

• Incretin-based therapies
• Type 2 diabetes
• Cardiometabolic health
• Primary care strategies
• Healthcare education

Keywords

• incretin
• Type 2 diabetes
• cardiometabolic health
• primary care
• continuing education
• healthcare professionals
• CME
• AAPA

Sponsors

Lilly

Mentioned in this episode

Organizations: PVI, PeerView Institute for Medical Education, Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), American Nurses Credentialing Center (ANCC)

More episodes of PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

• Athena Philis-Tsimikas, MD - Betting on Basal Insulin: Improving the Odds for People With Type 2 Diabetes (Updates From Las Vegas) · May 25, 2026 · 1h 9m
• Christina Y. Weng, MD, MBA - Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies · May 12, 2026 · 36 min
• Prof. Chantal Mathieu, MD, PhD - Betting on Basal Insulin: Improving the Odds for People With Type 2 Diabetes · April 3, 2026 · 1h 7m
• Peter A. Campochiaro, MD / Diana V. Do, MD - Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing · March 24, 2026 · 57 min
• John B. Buse, MD, PhD / Pam R. Taub, MD, FACC, FASPC - To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies · November 20, 2025 · 1h 4m
• Arun J. Sanyal, MBBS, MD - Making Connections to Improve Patient Care in Obesity, Metabolism, and Liver Health · October 30, 2025 · 44 min